Effects of Timolol and Latanoprost on Respiratory and Cardiovascular Status in Elderly Patients With Glaucoma

dc.contributor.authorErgin, Ahmet
dc.contributor.authorÖrnek, Kemal
dc.contributor.authorGüllü, Reyhan
dc.contributor.authorBulcun, Emel
dc.contributor.authorEkici, Mehmet
dc.contributor.authorEkici, Aydanur
dc.date.accessioned2020-06-25T17:48:14Z
dc.date.available2020-06-25T17:48:14Z
dc.date.issued2009
dc.departmentKırıkkale Üniversitesi
dc.description.abstractPurpose: To investigate the respiratory and cardiovascular effects of switching therapy from topical timolol 0.5% to latanoprost 0.005% in elderly patients with glaucoma. Methods: Twenty-five patients with primary open-angle glaucoma (POAG) who were treated with topical timolol 0.5% were included in the study. The beta-blocker treatment was ended due to insufficient intraocular pressure (IOP) and systemic or local side effects. The treatment then switched to latanoprost in these patients. All recruited patients underwent a full ocular, cardiovascular, and respiratory examination including spirometry, pulse rate, and blood pressure. All measurements were made 1 day before the beta-blocker treatment was ended and 30 days after the latanoprost treatment was started. Results: Timolol treatment was associated with numerically but not statistically significant lowered pulse rates, systemic blood pressure, diastolic blood pressure, and reductions in the spirometry measurements. The change to latanoprost treatment was associated with numerical improvement in mean values of spirometric test results. There were no significant differences in changes in mean values of spirometry, pulse rate, or blood pressure. Histamine challenge test was determined to be positive in 16 of 25 patients for timolol, of whom 10 were positive for latanoprost. This was statistically significant (P < 0.05). Conclusions: Although all the results presented were statistically insignificant, switching to latanoprost treatment may offer some advantages in respiratory and cardiovascular function for elderly people with glaucoma over beta-blocker drugs. Spirometry and the measurement of pulse rate and blood pressure are advised in all patients receiving topical beta-blocker therapy.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1089/jop.2008.0137
dc.identifier.endpage466en_US
dc.identifier.issn1080-7683
dc.identifier.issn1557-7732
dc.identifier.issue5en_US
dc.identifier.pmid19552600
dc.identifier.scopus2-s2.0-70350447794
dc.identifier.scopusqualityQ1
dc.identifier.startpage463en_US
dc.identifier.urihttps://doi.org/10.1089/jop.2008.0137
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4370
dc.identifier.volume25en_US
dc.identifier.wosWOS:000271143000012
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofJournal Of Ocular Pharmacology And Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleEffects of Timolol and Latanoprost on Respiratory and Cardiovascular Status in Elderly Patients With Glaucomaen_US
dc.typeArticle

Dosyalar